0C8 Stock Overview
Develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Catalent, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$53.40 |
| 52 Week High | US$57.00 |
| 52 Week Low | US$31.20 |
| Beta | 1.16 |
| 11 Month Change | -2.45% |
| 3 Month Change | -0.56% |
| 1 Year Change | 63.05% |
| 33 Year Change | -49.14% |
| 5 Year Change | 20.27% |
| Change since IPO | 250.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0C8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -1.8% | -1.8% |
| 1Y | 63.1% | -12.8% | 13.6% |
Return vs Industry: 0C8 exceeded the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: 0C8 exceeded the German Market which returned 13.6% over the past year.
Price Volatility
| 0C8 volatility | |
|---|---|
| 0C8 Average Weekly Movement | 1.7% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0C8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0C8's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 16,900 | Alessandro Maselli | www.catalent.com |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Catalent, Inc. Fundamentals Summary
| 0C8 fundamental statistics | |
|---|---|
| Market cap | €9.77b |
| Earnings (TTM) | -€955.81m |
| Revenue (TTM) | €4.01b |
2.4x
P/S Ratio-10.2x
P/E RatioIs 0C8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0C8 income statement (TTM) | |
|---|---|
| Revenue | US$4.38b |
| Cost of Revenue | US$3.43b |
| Gross Profit | US$953.00m |
| Other Expenses | US$2.00b |
| Earnings | -US$1.04b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.75 |
| Gross Margin | 21.75% |
| Net Profit Margin | -23.81% |
| Debt/Equity Ratio | 126.9% |
How did 0C8 perform over the long term?
See historical performance and comparison